Dr. Reddy's Laboratories Limited

NYSE:RDY

Drug Manufacturers - Specialty & Generic

Healthcare
$14.98 -1.13%

-$0.15 today

Market cap
$12.48B
Beta
0.26
P/E (TTM)
24.7
EPS (TTM)
$51.40
Dividend yield
0.63%
52W Low $12.19High $15.71

Volume 1.79M

Average 2.39M

RDY Pre-Tax Margin

Income before tax as a percentage of revenue.

Dr. Reddy's Laboratories LimitedNYSE: RDY

Pre-Tax Margin · Q2 FY2027 · quarter ended Sep 2026

Pre-tax margin narrows to 14.2%

Pre-tax margin was 14.2% in Q2 FY2027, down 6.7 pp from a year earlier. On a trailing-twelve-month basis it was 10.6%, down 11.6 pp year over year. Over 3 fiscal years it narrowed by 8.2 pp.

Context

  • Pre-tax margin widened in 1 of the last 3 fiscal years.
  • FY2026 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
14.2%+7.3 pp QoQ
Last fiscal yearMar 2026
16.3%-7.3 pp YoY
LTMSep 2026
10.6%-11.6 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-6.7 pp——
1 year-7.3 pp——
3 years-8.2 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2026
16.3%
Year-over-year change
-7.3pp

Pre-Tax Margin vs competitors

How RDY compares with its peers on the latest reported figures

  • RDY's LTM Sep 2026 pre-tax margin of 10.6% is the 4th highest of the 8 companies compared; the peer median is 6.5%.
  • Its year-over-year change of -11.6 pp is the lowest of 7, against a peer median of +4.0 pp.
  • Over three fiscal years its change of -8.2 pp compares with a peer median of +5.2 pp.
RDY Competitors Peer median
Pre-Tax Margin for RDY and competitors
Company Period LTM level YoY 3-year change
HLNHaleon plcLTM Jun 202519.1% —+4.6 pp
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 202614.3% -9.5 pp-5.8 pp
ANIPANI Pharmaceuticals, Inc.LTM Mar 202612.6% +16.6 pp+30.7 pp
RDYDr. Reddy's Laboratories LimitedLTM Sep 202610.6% -11.6 pp-8.2 pp
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 20266.5% +3.3 pp+15.8 pp
TEVATeva Pharmaceutical Industries LimitedLTM Jun 20264.2% +4.6 pp+28.2 pp
VTRSViatris Inc.LTM Jun 2026-4.5% +22.1 pp-42.9 pp
BHCBausch Health Companies Inc.LTM Jun 2026-6.7% -9.6 pp+5.2 pp
Peer median (excluding RDY) 6.5%+4.0 pp+5.2 pp

Competitors are the stored peer set for RDY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

INR
Metric
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Revenue214.39B245.88B279.16B325.54B353.47B
Cost of Revenue100.55B106.54B115.56B135.11B166.95B
Gross Profit113.84B139.34B163.61B190.43B186.52B
Gross Margin53.1%56.7%58.6%58.5%52.8%
Research & Development17.48B19.38B22.87B27.38B25.31B
Selling, General & Admin62.08B68.03B77.2B93.87B112.34B
Operating Expenses84.36B82.2B95.88B118.59B137.65B
Depreciation & Amortization11.82B12.64B14.84B17.06B21.68B
EBITDA45.08B74.43B88.42B96.67B83.29B
EBITDA Margin21.0%30.3%31.7%29.7%23.6%
Operating Income29.48B57.14B67.73B71.84B48.87B
Operating Margin13.7%23.2%24.3%22.1%13.8%
Interest Income965M1.18B2.28B2.68B8.28B
Interest Expense958M1.43B1.71B2.83B3.93B
Other Income / Expenses2.82B3.22B4.14B4.94B8.81B
Income Before Tax32.3B60.37B71.87B76.78B57.68B
Pre-Tax Margin15.1%24.6%25.7%23.6%16.3%
Income Tax Expense8.73B15.3B16.19B19.54B13B
Net Income23.57B45.07B55.68B56.54B45.09B
Net Margin11.0%18.3%19.9%17.4%12.8%
EPS (Basic)28.4254.2966.8067.8553.92
EPS (Diluted)28.3454.1766.8067.7753.92
Weighted Avg Shares829.41M830.17M833.54M833.31M832.41M
Weighted Avg Shares (Diluted)831.69M831.91M833.54M834.3M833.26M

Dr. Reddy's Laboratories Limited

NYSE:RDY

Intrinsic Alpha fair value

Locked

Current Price

$14.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.